Sandoz Shreds AbbVie's 'Misleading' Biosimilar Petition
Sandoz is tearing into AbbVie's recent call for the FDA to require exhaustive research before deeming biosimilars interchangeable with brand-name counterparts, saying it relies on "misrepresented and misleading" information....To view the full article, register now.
Already a subscriber? Click here to view full article